000			01911 a2200481 4500
005			20250514002835.0
264		0	_c20010712
008			200107s 0 0 eng d
022			_a0140-6736
024	7		_a10.1016/s0140-6736(00)05092-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aWan Po, A L
245	0	0	_aToo much, too little, or none at all: dealing with substandard and fake drugs. _h[electronic resource]
260			_bLancet (London, England) _cJun 2001
300			_a1904 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Comment
650	0	4	_aAbciximab
650	0	4	_aAdministration, Oral
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAspirin _xadministration & dosage
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Therapy, Combination
650	0	4	_aDrug and Narcotic Control _xlegislation & jurisprudence
650	0	4	_aFemale
650	0	4	_aFibrinolytic Agents _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xadministration & dosage
650	0	4	_aInfusions, Intravenous
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyocardial Infarction _xdrug therapy
650	0	4	_aMyocardial Reperfusion
650	0	4	_aPlatelet Aggregation Inhibitors _xadministration & dosage
650	0	4	_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors
650	0	4	_aRecombinant Proteins _xadministration & dosage
650	0	4	_aSurvival Rate
650	0	4	_aThrombolytic Therapy
650	0	4	_aTissue Plasminogen Activator _xadministration & dosage
773	0		_tLancet (London, England) _gvol. 357 _gno. 9272 _gp. 1904
856	4	0	_uhttps://doi.org/10.1016/s0140-6736(00)05092-3 _zAvailable from publisher's website
999			_c11354957 _d11354957